Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.
Alan P. Z. Skarbnik, MD, a hematologist/oncologist at Novant Health, discusses future combination therapies with tazemetostat (Tazverik) in follicular lymphoma.
Tazemetostat is a fairly well-tolerated treatment and has the potential to be combined with other therapies that are available, says Skarbnik. Typically in the drug development process, investigators will start with a well-tolerated single agent, which is then brought into earlier lines of therapy to see whether it can perform effectively when combined with other treatment regimens, according to Skarbnik.
Ongoing trials are examining tazemetostat plus chemoimmunotherapy for patients with relapsed follicular lymphoma. There appears to be a synergistic effect when tazemetostat is added to chemoimmunotherapy, although more data are needed to understand how this combination will be utilized and if it will be safe, says Skarbnik. More data are needed, but that is an exciting area of research, concludes Skarbnik.